Inoue S, Oishi M (2005)
A counteracting agent may be the stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419, an anti-ulcer peptide per-orally active (12-15) that may also affect many central disturbances (16-23), efficient in inflammatory bowel disease trials (PL 14736) (24, 25) and various wound treatment (26-28), no toxicity reported (12, 13, 24, 25)) which showed various hepatoprotective effects (29-31)
Target Areas: BPC 157 vs Sermorelin Increasing growth hormone with Sermorelin impacts the body on a systemic level
Furthermore, the optimal timing and sequencing of SFN administration in combination therapies require careful consideration
Most of the SERP is dominated by shopping listicles from beauty media, e-commerce product pages on Amazon and Sephora, telehealth brands selling topical scalp serums, and a small number of peer-reviewed academic papers